ArticleEClinicalMedicine2020
Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care.
Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06928935 (Digital Dialectical Behavioural Therapy), which is not on this map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis: An Exploratory Multi-Methods Study
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.Molecular psychiatry · 2022Pooled it
- Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.Epidemiology and psychiatric sciences · 2022Pooled it
- Clinical outcomes in brief psychotic episodes: a systematic review and meta-analysis.Epidemiology and psychiatric sciences · 2021Pooled it
- Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?The international journal of neuropsychopharmacology · 2021Pooled it
- Subcategories of the Clinical High-Risk State for Psychosis and Their Relationship to a Full First-Episode Psychosis Sample: An Exploratory Analysis of Longitudinal Outcomes.Schizophrenia bulletin · 2026Article
- Predicting long-term poor outcomes in individuals at clinical high risk for psychosis using real-world clinical data: the OASIS1000 prospective study.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Validation of the cognitive fusion questionnaire in regular meditators and persons with schizophrenia spectrum disorders.Frontiers in psychology · 2026Article
- Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview.Indian journal of psychiatry · 2026Article
- Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for Psychosis.Schizophrenia bulletin · 2025Observational
- The ENTER study (E-DetectioN Tool for Emerging Mental DisoRders): general population recruitment and data integrity in online screening for psychosis risk.Frontiers in psychiatry · 2025Article
- Article
- A transdiagnostic prodrome for severe mental disorders: an electronic health record study.Molecular psychiatry · 2024Article
- Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning.Schizophrenia research · 2024Article
- Physical Health and Transition to Psychosis in People at Clinical High Risk.Biomedicines · 2024Article
- Article
- Establishing a business case for setting up early detection services for preventing psychosis.BJPsych bulletin · 2023Review
- Physical Health in Clinical High Risk for Psychosis Individuals: A Cross-Sectional Study.Brain sciences · 2023Article
- Neuroanatomical heterogeneity and homogeneity in individuals at clinical high risk for psychosis.Translational psychiatry · 2022Article
- Antipsychotics are related to psychometric conversion to psychosis in ultra-high-risk youth.Early intervention in psychiatry · 2022Article
- Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study.European archives of psychiatry and clinical neuroscience · 2022Observational
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 3 countries.
Funding
Abstract
backgroundMost services for individuals at Clinical High Risk for Psychosis (CHR-P) provide short-term clinical care. This study determines the real-world and long-term clinical outcomes beyond transition to psychosis in a large cohort of CHR-P individuals.
methodRetrospective RECORD-compliant real-world Electronic Health Records (EHR) cohort study in secondary mental health care (the South London and the Maudsley -SLaM- NHS Foundation Trust). All CHR-P patients accessing the CHR-P service at SLaM in the period 2001-2018 were included. Main outcomes were long-term cumulative risk of first: (i) developing an ICD-10 psychotic disorder (primary outcome), receiving a treatment with (iia) antipsychotic medication, (iib) benzodiazepines, (iic) other psychotropic medications, (iid) psychotherapy, receiving an (iiia) informal or (iiib) compulsory admission into a mental health hospital, and the time to these events; (iiic) number of days spent in hospital and (iv) cumulative risk of death for any reason and age/gender Standardised Mortality Ratio (SMR). Data were extracted from the EHR and analysed with Kaplan Meier failure functions, Cox and zero-inflated negative binomial regressions.
findings600 CHR-P patients (80.43% Attenuated Psychotic Symptoms, APS; 18.06%, Brief and Limited Intermittent Psychotic Symptoms, BLIPS, 1.51% Genetic Risk and Deterioration Syndrome) were included (mean age 22.63 years, range 13-36; 55.33% males; 46.44% white, mean duration of untreated attenuated psychotic symptoms 676.32 days, 1105.40 SD). The cumulative risk to first psychosis was 0.365 (95%CI 0.302-0.437) at 11 years; first antipsychotic 0.777 (95%CI 0.702-0.844) at 9 years; first benzodiazepine 0.259 (95%CI 0.183-0.359) at 12 years; first other types of medications 0.630 (95%CI 0.538-0.772) at 9 years; first psychotherapy 0.814 (95%CI 0.764-0.859) at 9 years; first informal admission 0.378 (95%CI 0.249-0.546) at 12 years; first compulsory admission 0.251 (95%CI 0.175-0.352) at 12 years; those admitted spent on average 94.84 (SD=169.94) days in hospital; the cumulative risk of death for any reason was 0.036 (95%CI 0.012-0.103) at 9 years, with an SMR of 3.9 (95%CI 1.20-6.6). Compared to APS, BLIPS had a higher risk of developing psychosis, being admitted compulsorily into hospital, receiving antipsychotics and benzodiazepines and lower probability of receiving psychotherapy. Other prognostic factors of long-term outcomes included age, symptoms severity, duration of untreated attenuated psychotic symptoms, ethnicity and employment status.
interpretationDuration of care provided by CHR-P services should be expanded to address long-term real-world outcomes.
fundingThis study was supported by the King's College London Confidence in Concept award from the Medical Research Council (MRC) (MC_PC_16048) to PF-P. GSP is supported by the Alicia Koplowitz Foundation. HB is supported by a National Institute for Health Research Maudsley Biomedical Research Centre studentship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.